Organization
Shanghai Biomabs Pharmaceutical
2 clinical trials
Clinical trial
Randomized, Doubel-blinded, Parallel, Active-controlled Phase III Study, to Evaluate the Efficacy and Safety of CMAB807 Treatment Compared With Prolia® in Chinese Postmenopausal Women With Osteoporosis at High Risk of Fracture.Status: Recruiting, Estimated PCD: 2024-10-01